INBS vs. SURG, EDAP, QTI, ECOR, APT, INO, MLSS, DXR, TMDIF, and NMTC
Should you be buying Intelligent Bio Solutions stock or one of its competitors? The main competitors of Intelligent Bio Solutions include SurgePays (SURG), Edap Tms (EDAP), QT Imaging (QTI), electroCore (ECOR), Alpha Pro Tech (APT), Inovio Pharmaceuticals (INO), Milestone Scientific (MLSS), Daxor (DXR), Titan Medical (TMDIF), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.
Intelligent Bio Solutions vs. Its Competitors
SurgePays (NASDAQ:SURG) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
SurgePays has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.6, indicating that its stock price is 360% more volatile than the S&P 500.
Intelligent Bio Solutions has lower revenue, but higher earnings than SurgePays.
6.9% of SurgePays shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 30.5% of SurgePays shares are held by insiders. Comparatively, 1.5% of Intelligent Bio Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, SurgePays and SurgePays both had 4 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.84 beat SurgePays' score of 0.76 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.
SurgePays currently has a consensus target price of $9.00, suggesting a potential upside of 206.12%. Given SurgePays' stronger consensus rating and higher possible upside, equities analysts plainly believe SurgePays is more favorable than Intelligent Bio Solutions.
SurgePays has a net margin of -136.37% compared to Intelligent Bio Solutions' net margin of -319.85%. Intelligent Bio Solutions' return on equity of -176.55% beat SurgePays' return on equity.
Summary
Intelligent Bio Solutions beats SurgePays on 7 of the 13 factors compared between the two stocks.
Get Intelligent Bio Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intelligent Bio Solutions Competitors List
Related Companies and Tools
This page (NASDAQ:INBS) was last updated on 7/26/2025 by MarketBeat.com Staff
